ClinicalTrials.gg
CompletedNCT03187990Updated Sep 2, 2021

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

An interventional study of [68Ga]PSMA-11 and [18F]PSMA-1007 in Prostate Cancer, sponsored by Irene Burger. Completed at 1 site in Switzerland. Open to male participants aged 30 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-02.

Sponsored by Irene Burger · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2017, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.

Enrollment
70th of 107
52 · median 140
Started
2017
with 10 others
No phase
23 of 136
8 open now
Registered
64th of 136
by date

Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 70th largest by enrollment of the 107 interventional ones that give a count, is one of 11 that started in 2017, is one of 23 with no phase, and was the 64th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Prostatic Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or pN1). Therefore this study evaluates the ability of [68Ga]PSMA PET/MRI to detect and localize significant primary PCA to accurately direct prostate needle biopsy using the Gleason score from the histology of the core biopsies as standard of truth.

Read the detailed description

In this open label, single center, non-randomized, diagnostic study we plan to include 40 men with elevated PSA (ages 30-50 PSA >2.5 ng/mL; ages 50-80 PSA > 4ng/mL), which are assigned to a MRI guided biopsy.

These patients will undergo one additional PET/MRI scan with [68Ga]PSMA within two to three weeks before the biopsy (Arm A), or in case of an unclear/negative MRI scan but positive biopsy two to three weeks after biopsy (Arm B). In Arm A a radiologist will delineate the suspected areas on (A) multiparametric magnetic resonance image (mpMRI) and a nuclear medicine physician will delineate and color code the suspicious areas on the PET/MRI: (B) [68Ga]PSMA. The images will be loaded into the BiopSee® system. Lesions positive on both modalities will be labeled as "AB". Every suspicious lesion will be targeted with 3 cores. A maximum of 3 targets will be selected per patient.

For arm B: PET/MRI results will be correlated with the template biopsy results.

The data analysis of Arm A and Arm B will be identical. For the analysis the Gleason score from the histology of the core biopsies will serve as standard of truth.

After completion of the PET/MR study part - an amendment for PET/CT was submitted to the local ethics commity and acknowledged to include 10 more participants with PSMA PET/CT to investigate the use of PET/CT guided biopsy and intraoperative verivication of the target with a gamma counter.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • PSMA PET/MRI
  • Guided Biopsy
  • Prostate Cancer
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously undiagnosed patients with elevated PSA (ages 30-50 PSA >2.5 ng/mL; ages 50-80 PSA > 4ng/mL), eligible for prostate needle .
  2. Patients can have negative prior needle biopsy(ies) for suspected prostate cancer
  3. mpMRI with at least one suspicious target lesion (Arm A), or negative mpMRI but positive biopsy (Arm B).
  4. Written
  5. Age > 30

Exclusion criteria

Exclusion Criteria:

  1. Age> 80
  2. to MRI or prostate (e.g. extreme claustrophobia, metallic implants incompatible with MRI, anatomical contraindications, coagulopathy, severe medical comorbidity prohibiting halting of anticoagulation therapies)
  3. Active urinary tract infection or indwelling catheter
  4. Prior pelvic irradiation
  5. Prior prostatectomy
  6. Prior androgen deprivation hormonal therapy
  7. Prostate biopsy within 8 weeks prior to study
  8. Prior transurethral resection of the prostate (TURP)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    PET/MRI before biopsy

    Patients with suspected areas on mpMRI will undergo additional \[68Ga\]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.

    Drug: [68Ga]PSMA-11 · Drug: [18F]PSMA-1007

  • Experimental
    PET/MRI after biopsy

    Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional \[68Ga\]PSMA-11 PET/MRI scan with \[68Ga\]PSMA.

    Drug: [68Ga]PSMA-11

Interventions

  • Drug[68Ga]PSMA-11

    PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.

    Also known as: PSMA PET/MRI

  • DrugPSMA-1007Studies of PSMA-1007PSMA-1007 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.

    Also known as: PSMA PET/CT

06

What researchers measure

Primary outcomes

  1. Rate of positive histopathology for [68Ga]PSMA-11 positive lesions

    PCA detection of PET/MRI versus mpMRI based on histopathology per patient and per prostate section.

    Time frame: 7 months

Secondary outcomes

  1. Correlation of [68Ga]PSMA-11 with tumor aggressiveness

    Correlation of stanadized uptake value (SUV) on \[68Ga\]PSMA-11 with Gleason Score on histopathology.

    Time frame: 7 months

07

Study locations

1 site
  • University Hospital Zurich
    Zurich, 8091, Switzerland
08

References and documents

Publications

  • Ferraro DA, Laudicella R, Zeimpekis K, Mebert I, Muller J, Maurer A, Grunig H, Donati O, Sapienza MT, Rueschoff JH, Rupp N, Eberli D, Burger IA. Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1721-1730. doi: 10.1007/s00259-021-05599-3. Epub 2021 Nov 2. PubMed 34725726 ↗
  • Ferraro DA, Becker AS, Kranzbuhler B, Mebert I, Baltensperger A, Zeimpekis KG, Grunig H, Messerli M, Rupp NJ, Rueschoff JH, Mortezavi A, Donati OF, Sapienza MT, Eberli D, Burger IA. Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3315-3324. doi: 10.1007/s00259-021-05261-y. Epub 2021 Feb 23. PubMed 33620559 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Aug 2021, 53 months.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 53 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2017
First posted
Jun 15, 2017
StartActual
Mar 3, 2017
Primary completionActual
Aug 3, 2021
CompletionActual
Aug 3, 2021
Last update
Sep 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03187990
Lead sponsor
Irene Burger
Responsible party
Irene Burger (Principal investigator, University of Zurich) — Sponsor-investigator
First posted
Jun 15, 2017
Start date
Mar 3, 2017
Primary completion
Aug 3, 2021
Completion
Aug 3, 2021
Last update
Sep 2, 2021

Study contacts

Irene A Burger, MD
principal investigator · UniversitaetsSpital Zuerich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PSMA-1007

Start the discussion